Quality of Life and its Relationship with Perceived Stigma among Opioid Use Disorder Patients: An Exploratory Study

Swarndeep Singh, Saurabh Kumar, Siddharth Sarkar, Yatan Pal Singh Balhara

ABSTRACT

Background: In view of recent global opioid epidemic and scarcity of literature assessing the quality of life (QoL) and stigma among opioid use disorder (OUD) patients, this study aimed to assess the overall QoL and examine its relationship with perceived stigma among them. Materials and Methods: This cross-sectional study assessed patients with OUD at a tertiary care centre. QoL was assessed using the World Health Organization Quality of Life-brief version, whereas perceived stigma was measured using the Perceived Stigma of Substance Abuse Scale (PSAS). Results: Among 168 patients with OUD, all the four domain-wise scores of physical health ($r = 0.79, P < 0.01$), psychological health ($r = 0.87, P < 0.01$), social relationships ($r = 0.78, P < 0.01$) and environment ($r = 0.80, P < 0.01$) QoL correlated significantly with average score, with maximum impairment noted in the social domain. The mean PSAS score was 21.19 ± 2.99, with perceived stigma found to be significantly associated with impairments in the physical ($\beta = -0.28, P < 0.01$), psychological ($\beta = -0.27, P < 0.01$) and environment ($\beta = -0.21, P < 0.01$) domains of QoL. Furthermore, being employed was significantly associated with impairment in the social domain of QoL ($\beta = -0.17, P = 0.02$). Conclusion: OUD similarly affects all the four domains of QoL, with a higher level of perceived stigma associated with significantly poorer QoL in the physical, psychological and environment domains. However, future studies assessing different forms of stigma and QoL among patients with OUD are needed to confirm and better characterise the findings of this study.

Key words: Opioid use disorders, perceived stigma, quality of life, WHOQOL-BREF

INTRODUCTION

Substance use disorders (SUDs) are chronic relapsing conditions which negatively affect the patient’s physical and mental health, societal and family functioning, employment and residential status and access to services. The emergence of high-potency synthetic opioid preparations such as heroin and relative

This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.

For reprints contact: reprints@medknow.com

How to cite this article: Singh S, Kumar S, Sarkar S, Balhara YP. Quality of life and its relationship with perceived stigma among opioid use disorder patients: An exploratory study. Indian J Psychol Med 2018;40:556-61.
ease of access to opioids has led to a global opioid abuse epidemic, with an estimated 26.4–36 million people suffering from opioid use disorders (OUDs) worldwide.\textsuperscript{[3]} In the United States alone, opioid overdose-related death rates have increased by about 200% from 2000 to 2014.\textsuperscript{[4]} Furthermore, OUDs are also responsible for significant financial burden caused by the healthcare-, workplace- and criminal-justice-related costs.\textsuperscript{[5]} National Drug Use Survey Report estimated that opioids were responsible for the largest proportion of illicit patients with SUD seeking treatment in India.\textsuperscript{[6]} Thus, the problem of opioid abuse has reached epidemic proportions, and research on various aspects of OUDs is needed to better understand their overall impact and develop more effective intervention strategies for their control.

The World Health Organization (WHO) defines the quality of life (QoL) as ‘individuals’ perception of their position in life in the context of the culture and value systems in which they live and in relation to their goals, expectati ons, standards and concerns’.\textsuperscript{[7]} The QoL provides an empirical assessment of how patients experience functioning in various domains of their life and the effect of treatment on SUD-related burden, which is not captured by traditional substance use symptom-based assessment instruments.\textsuperscript{[8]} Furthermore, higher pretreatment QoL has been shown to predict better outcomes in patients with SUDs.\textsuperscript{[9]} Thus, QoL is being increasingly recognised as an important construct in SUD research and clinical practice.\textsuperscript{[10]}

Stigma can be understood as a sociocultural phenomenon in which specific social groups are devalued, rejected and excluded on the basis of a socially discredited health condition.\textsuperscript{[11]} SUDs are associated with significant social disapproval and discrimination, and patients with a SUD are less likely to be offered help by other individuals in the society than those who have a mental illness or physical disability.\textsuperscript{[12]} The available literature suggests that substance users experience various distinct forms of stigma, including enacted, internalised and perceived stigma.\textsuperscript{[13]} Perceived stigma refers to the extent to which members of a stigmatised group believe that others hold common negative stereotypes about individuals belonging to their stigmatised category.\textsuperscript{[14]} Perceived stigma among patients with SUD is an important area to study since higher levels of perceived stigma have been reported to be associated with greater treatment delay and poorer treatment adherence.\textsuperscript{[15,16]}

However, so far only a limited number of studies have assessed the overall QoL and perceived stigma specifically among patients with OUD, and the majority of them have been conducted in Western settings. Hence, this study aimed to assess the overall QoL and examine its relationship with perceived stigma among patients with OUD seeking treatment at a tertiary care centre in India.

**MATERIALS AND METHODS**

**Study settings and participants**

This is an exploratory study with a cross-sectional design, conducted at a public-funded tertiary care centre in North India. The centre provides both inpatient and outpatient treatment services. The inclusion criteria were between 18 and 65 years, a clinical diagnosis of OUD made by a trained psychiatrist according to Diagnostic and Statistical Manual 5 criteria, and using the substance other than nicotine or moderate to severe withdrawal symptoms at the time of assessment and those who refused to give informed written consent were excluded. (Patients with moderate to severe withdrawal symptoms were excluded so that the assessment values were more holistic and not influenced by the acute withdrawal state.)

**Study procedure**

Patients attending the outpatient or inpatient treatment settings were approached and explained about the nature of the study. Those who agreed to participate and gave informed written consent were assessed for inclusion. The participants were recruited by purposive sampling over a period of 12 months. The details about sociodemographic and clinical characteristics were gathered using a semi-structured proforma. The Hindi version of World Health Organization Quality of Life-brief version (WHOQOL-BREF) was used to assess the QoL across various domains, and Perceived Stigma of Substance Abuse Scale (PSAS) was used to measure the perceived stigma. Data collection was carried out by trained psychiatrists in a single sitting. The study was approved by the Institutional Ethics Committee.

**Instruments**

**Semi-structured proforma**

This was developed for this study and used to record details about the sociodemographic profile and relevant clinical details of the study participants. It included information related to substance use pattern and a few other related complications such as a history of injecting drug use (IDU), engaging in high-risk behaviours or drug peddling, or any pending legal issues.

**World Health Organization Quality of Life-brief version (WHOQOL-BREF)**

This internationally validated instrument consists of 26 items, of which 24 items measure four potentially independent QoL domains of physical health, psychological health, social relationships and environment.\textsuperscript{[17]} The two remaining WHOQOL-BREF
items rate overall subjective QOL and satisfaction with health and were not used in this study. The physical health domain includes questions pertaining to sleep, energy, mobility, the extent to which pain prevents the performance of necessary tasks, need for medications to function in daily life and level of satisfaction with one’s capacity for work. The psychological domain focuses on the ability to concentrate, self-esteem, body image, spirituality and the frequency of positive or negative feelings. The social relationships domain includes questions pertaining to satisfaction with personal relationships, social support system and sexual satisfaction. The environment domain includes questions related to safety and security, home and physical environment satisfaction, financial security, health/social care availability, information and leisure activity accessibility and transportation satisfaction.\[18\] The statements of this questionnaire were rated on a 5-point Likert scale. The mean scores of items in each domain were used to calculate the domain score, which were transformed into a 20-point scale before analysis. Thus, higher domain scores denote a better QoL. The Hindi version of WHOQOL-BREF has been validated previously and has a mean reliability estimate of 0.89.\[19\]

**Perceived Stigma of Substance Abuse Scale (PSAS)**

This scale consists of eight items scored on a 4-point Likert scale between 1 (strongly disagree) to 4 (strongly agree). This scale assesses stigma perceived by subjects toward substance users. Item scores were combined to obtain a total score between 8 and 32, where higher scores indicated more perceived stigma. This scale has good convergent and discriminant validity, and adequate internal consistency (\(\alpha = 0.73\)).\[14\] It has been used to assess perceived stigma among substance users and patients with OUD specifically.\[20\] The Hindi translated version of the instrument is available and was used in this study.\[21\]

**Statistical analysis**

Statistical analysis was done using SPSS version 23.0 (IBM Corp., Armonk, NY, USA). Descriptive statistics using mean, standard deviation, frequency and percentage were used to describe the sample characteristics and scores on different scales. Pearson’s correlation was used to determine the level of agreement between the four domains of WHOQOL-BREF and average QoL score. Bivariate analysis using Pearson’s correlation and independent t-test was conducted to examine the associations between measures of QoL, perceived stigma and other sociodemographic and clinical variables. Multiple linear regression analyses were carried out separately to examine perceived stigma and other significant variables as potential independent factors affecting the various domains of QoL. A P value of less than 0.05 was considered significant, and all the tests were two-tailed. Missing data were not encountered, and the interviewers were checked for completion during data gathering.

**RESULTS**

A total of 199 individuals with OUD were approached, and 168 were finally included. Among the 31 individuals who were excluded, 18 were having moderate to severe withdrawal symptoms at the time of assessment, 11 had comorbid SUD other than nicotine and 2 refused to participate.

The sociodemographic and clinical characteristics of the study participants are included in Table 1. The study participants comprised almost exclusively of males, and the majority of them were employed and stayed at an urban residence.

### Table 1: Demographic and clinical characteristics of the study participants (n=168)

| Variable                               | Mean±SD or frequency (percentage) |
|----------------------------------------|----------------------------------|
| Age in years                           | 31.77±10.33                      |
| Gender                                 |                                  |
| Male                                   | 167 (99.4%)                      |
| Female                                 | 1 (0.6%)                         |
| Education                              |                                  |
| Up to 10th standard                    | 114 (67.9%)                      |
| Above 10th standard                    | 54 (32.1%)                       |
| Employment status                      |                                  |
| Employed                               | 142 (84.5%)                      |
| Not employed                           | 26 (15.5%)                       |
| Place of residence                     |                                  |
| Urban                                  | 137 (81.5%)                      |
| Rural                                  | 31 (18.5%)                       |
| Family type                            |                                  |
| Nuclear                                | 101 (60.1%)                      |
| Extended/joint                         | 67 (39.9%)                       |
| Duration of substance use in years     | 10.23±8.09                       |
| Injecting drug use                     |                                  |
| No                                     | 111 (66.1%)                      |
| Yes                                    | 57 (33.9%)                       |
| High-risk behaviour                    |                                  |
| No                                     | 149 (88.7%)                      |
| Yes                                    | 19 (11.3%)                       |
| Caught by police                       |                                  |
| No                                     | 129 (76.8%)                      |
| Yes                                    | 39 (23.2%)                       |
| Incarceration                          |                                  |
| No                                     | 144 (85.7%)                      |
| Yes                                    | 24 (14.3%)                       |
| Legal case pending                     |                                  |
| No                                     | 159 (94.6%)                      |
| Yes                                    | 9 (5.4%)                         |
| Drug peddling                          |                                  |
| No                                     | 164 (97.6%)                      |
| Yes                                    | 4 (2.4%)                         |

SD - Standard deviation
The mean and standard deviation values for various QoL measures are included in Table 2. The four domain-wise QoL scores for physical health (r = 0.79, P < 0.01), psychological health (r = 0.87, P < 0.01), social relationships (r = 0.78, P < 0.01) and environment (r = 0.80, P < 0.01) QoL correlated significantly with the average QoL score. The mean and standard deviation of PSAS score assessing perceived stigma were 21.19 and 2.99, respectively.

The results of Pearson’s correlation analysis assessing the relationship between the four domains of QoL, the age of participants, duration of substance use and perceived stigma are included in Table 3. The PSAS score showed a significantly negative correlation with the physical, psychological and environment domains of QoL. The environment domain of QoL showed a significantly negative correlation with the age of participants. The results of the independent t-test assessing the relationship of the four domains of QoL, with other sociodemographic and clinical variables are also described in Table 3. The mean physical QoL domain scores were significantly lower among patients involved in high-risk behaviour (Yes = 9.95 ± 2.14 and No = 11.29 ± 2.43; t = -2.289, P = 0.02) and drug peddling (Yes = 8.42 ± 4.18 and No = 11.20 ± 2.35; t = -2.287, P = 0.02). The mean psychological QoL domain score was significantly lower among patients with IDU (IDU = 10.54 ± 2.41 and non-IDU = 11.33 ± 2.25; t = -2.094, P = 0.03). The mean social QoL domain score was significantly higher among unemployed patients with OUD (Employed = 10.33 ± 2.69 and Unemployed = 11.74 ± 3.35; t = -2.333, P = 0.02).

Multiple linear regression analyses were carried out to examine perceived stigma as a potential influencing factor for the four domains of QoL [Table 4]. The transformed individual domain scores were entered as the dependent variables, with PSAS score and all the variables found to be significantly associated with various QoL domains in the bivariate analysis entered as independent variables. To check for multicollinearity, the tolerance statistic and variance inflation factor were examined, and they did not reveal significant multicollinearity. (The recommended maximum value of 10 for variation inflation factor and a minimum value of 0.1 for tolerance statistic were used as cut-offs for deciding the acceptable level of multicollinearity.) The results of these analyses showed that after controlling for other variables, perceived stigma was still significantly associated with impairments in physical, psychological and environment domains of QoL. Furthermore, being employed was significantly associated with impairment in the social domain of QoL.

### DISCUSSION

This study examined the pattern of impairments in different overall QoL domains among patients with OUD and explored the relationship between perceived stigma among patients and various domains of QoL. There was a significant correlation between all the four domains of physical health, psychological health, social relationships and environment QoL, with all

---

**Table 2: Results of quality of life assessment in study participants**

| WHOQOL measures | Mean ± standard deviation |
|-----------------|---------------------------|
| DOM-1 Physical  | 11.14 ± 2.43              |
| DOM-2 Psychological | 11.06 ± 2.33            |
| DOM-3 Social     | 10.55 ± 2.83              |
| DOM-4 Environment| 11.87 ± 2.46              |
| Average QoL      | 11.15 ± 2.04              |

**WHOQOL - World Health Organization Quality of Life; DOM - Domain**

**Table 3: Relationship between perceived stigma, sociodemographic and clinical characteristics with various QoL domains**

| Variables                        | QoL DOM-1 | QoL DOM-2 | QoL DOM-3 | QoL DOM-4 |
|----------------------------------|-----------|-----------|-----------|-----------|
| Age (years)                      | -0.100    | -0.106    | -0.102    | -0.158    |
| Education                        | -1.000    | -1.484    | -0.039    | 0.522     |
| Employed                         | 0.550     | -0.026    | -2.353    | -0.547    |
| Residence                        | -1.859    | -1.771    | -1.256    | -1.916    |
| Family type                      | -0.610    | -1.337    | 0.191     | -0.891    |
| Duration of Substance use (years)| -0.121    | -0.036    | -0.038    | -0.010    |
| Injecting drug use               | -1.949    | -2.094    | 0.990     | 0.170     |
| High-risk behaviour              | -2.289    | -1.493    | 0.523     | 0.487     |
| Caught by police                 | -0.830    | 0.41      | 0.929     | 0.802     |
| Incarceration                    | -0.763    | -0.300    | 0.001     | -0.306    |
| Legal case pending               | -0.844    | 0.157     | 0.120     | 0.009     |
| Drug peddling                    | -2.287    | -2.404    | -0.158    | -1.131    |
| PSAS score                       | -0.321    | <0.01**   | <0.01**   | <0.01**   |

QoL - Quality of life; DOM - domain; PSAS - Perceived Stigma of Substance Abuse Scale; *Pearson correlation coefficient; **Independent t-test;  
* P<0.05; ** P<0.01
four domain-wise scores showing significantly strong positive correlation with the average QoL score. This supports the biopsychosocial nature of OUD, which negatively affects multiple aspects of an individual’s life such as physical and mental health, education, family functioning, employment and housing. The maximum impairment in QoL was for the domain of social relationships, which assesses an individual’s satisfaction with personal relationships, social support and sexual activity, emphasising the social nature of the OUDs. These findings are similar to those reported in a previous study assessing the QoL among patients with OUD from a similar treatment setting in India.[22]

This study showed that a higher level of perceived stigma among patients with OUD is a potential influencing factor for impairment in the social QoL domain. This may be because employed patients with OUD were more likely to be in the company of persons not approving of substance use and had higher chances of facing both direct and indirect forms of discrimination at the workplace. This is supported by the findings from a previous study which reported a higher level of perceived stigma among employed patients with SUD.[20]

However, perceived stigma was not found to be a potential influencing factor for impairment in the social QoL domain. This suggests the possibility of some other factors not explored in this study to be affecting the social QoL domain. Moreover, the perceived stigma was explaining only about 5.7%–11.9% of the variance in impairments observed in the other three QoL domains. This might be because stigma is a multifaceted phenomenon which includes at least three conceptually different constructs of perceived stigma, enacted stigma and internalised stigma.[14] Thus, future studies should assess the effect of different forms of stigma on QoL simultaneously to better understand the relationship between them.

There is a paucity of research on SUD-related stigma when compared with the stigma associated with other mental illnesses such as depression or schizophrenia.[27] The limited available literature on SUD-related stigma is predominantly from Western settings, and findings from those studies need to be tested first, keeping in mind the different sociocultural factors existing in the context of developing non-Western countries like India.

In view of the multifaceted negative consequences of stigma in patients with SUD, this study assessed both the perceived stigma and the QoL simultaneously among patients with OUD using two standardised instruments with good psychometric properties. To the best of our knowledge, this is the first study so far which systematically assessed the relationship between perceived stigma and various domains of QoL. However, the findings of this study need to be interpreted keeping in mind its various limitations. The study was conducted at a single tertiary care centre with a purposive sampling of treatment seekers, comprising almost exclusively of males. Hence, generalisation if any should be done with caution. The study is cross-sectional in nature which does not allow us to explore the effect of treatment on QoL, which needs a longitudinal study. In addition, a control group comprising patients with some chronic physical/mental illness or normal population might have provided better comparative data and increased the robustness of the findings of this study. This study did not assess the severity of opioid use among patients, and hence the effect of severity of substance use on QoL could not be examined. Finally, social desirability bias

### Table 4: Multiple linear regression analyses results

| QoL measures | Variables in equation | B (P) | 95% CI for B |
|--------------|-----------------------|-------|-------------|
| DOM-1<sup>st</sup> | PSAS                  | -0.299 (<0.01)** | -0.349 to -0.109 |
|               | HRB                   | -1.006 (0.07)     | -2.116 to 0.104 |
|               | Drug peddling         | -1.746 (0.14)     | -4.079 to 0.587 |
| DOM-2<sup>nd</sup> | PSAS                  | -0.020 (<0.01)** | -0.325 to -0.005 |
|               | IDU                   | -1.589 (0.17)     | -3.892 to 0.715 |
|               | Drug peddling         | -0.575 (0.12)     | -1.304 to 0.154 |
| DOM-3<sup>rd</sup> | PSAS                  | -0.082 (0.26)     | -0.225 to 0.001 |
|               | Employed              | -1.369 (0.02)*    | -2.549 to -0.188 |
| DOM-4<sup>th</sup> | PSAS                  | -0.177 (0.005)**  | -0.300 to -0.054 |
|               | Age                   | -0.030 (0.09)     | -0.066 to 0.006 |

QoL - Quality of life; DOM - Domain; PSAS - Perceived Stigma of Substance Abuse Scale; HRB - High-risk behaviour; IDU - Injecting drug use; B: unstandardised coefficient; CI - Confidence interval. * P < 0.05; ** P < 0.01; *** Adjusted $R^2$ = 0.117 (F = 8.36; P < 0.01**); Adjusted $R^2$ = 0.103 (F = 7.38; P < 0.01*); ***Adjusted $R^2$ = 0.028 (F = 3.41; P = 0.03*); ****Adjusted $R^2$ = 0.059 (F = 6.27; P = 0.02*)
and respondent bias could not be fully removed due to the nature of the study.

However, despite these limitations, this study describes the pattern of overall QoL and perceived stigma among patients with OUD, with a higher level of perceived stigma associated with significantly poorer QoL in the physical, psychological and environment domains. Furthermore, future studies with larger sample size and longitudinal design, assessing the different forms of stigma and QoL among patients with OUD, are needed to confirm and better characterise the findings of this study.

Financial support and sponsorship
Nil.

Conflict of interest
There are no conflicts of interest.

REFERENCES

1. Degenhardt L, Whiteford HA, Ferrari AJ, Baxter AJ, Charlson FJ, Hall WD, et al. Global burden of disease attributable to illicit drug use and dependence: Findings from the global burden of disease study 2010. Lancet 2013;382:1564-74.
2. Rehm J, Mathers C, Popova S, Thavorncharoensap M, Teerawattananon Y, Patra J. Global burden of disease and injury and economic cost attributable to alcohol use and alcohol use disorders. Lancet 2009;373:2223-33.
3. United Nations Office on Drugs and Crime. World drug report; 2015. Available from: https://www.unodc.org/documents/wdr2015/World_Drug_Report_2015.pdf. [Last accessed on 2018 Mar 20].
4. Rudd RA, Aleshire N, Zibbell JE, Matthew Gladden R. Increases in drug and opioid overdose deaths – United States, 2000–2014. Am J Transplant 2016;16:1323-7.
5. Birnbaum HG, White AG, Schiller M, Waldman T, Cleveland JM, Roland CL. Societal costs of prescription opioid abuse, dependence, and misuse in the United States. Pain Med 2011;12:657-667.
6. Ray R. The extent, pattern and trends of drug abuse in India – National Survey. Regional Office for South Asia: Ministry of Social Justice and Empowerment, Government of India and United Nations Office on Drugs and Crime; 2004. Available from: http://www.unodc.org/pdf/india/presentations/india_national_survey_2004.pdf. [Last accessed on 2018 Mar 20].
7. The WHOQOL Group. The World Health Organization quality of life assessment (WHOQOL): Position paper from the World Health Organization. Soc Sci Med 1995;41:1403-9.
8. Donovan D, Mattson ME, Cisler RA, Longabaugh R, Zwebeen A. Quality of life as an outcome measure in alcoholism treatment research. J Stud Alcohol Suppl 2005;15:119-39.
9. Smith KW, Larson MJ. Quality of life assessments by adult substance abusers receiving publicly funded treatment in Massachusetts. Am J Drug Alcohol Abuse 2003;29:323-35.
10. Laudet AB. The case for considering quality of life in addiction research and clinical practice. Addict Sci Clin Pract 2011;6:44-55.
11. Weiss MG, Ramakrishna J, Somma D. Health-related stigma: Rethinking concepts and interventions 1. Psychol Health Med 2006;11:277-87.
12. Corrigan PW, Watson AC, Miller FE. Blame, shame and contamination: The impact of mental illness and drug dependence stigma on family members. J Fam Psychol 2006;20:239-46.
13. Link BG, Yang LH, Phelan JC, Collins PY. Measuring mental illness stigma. Schizophr Bull 2004;30:511-41.
14. Luoma JB, O’Hair AK, Kohlenberg BS, Hayes SC, Fletcher L. The development and psychometric properties of a new measure of perceived stigma toward substance users. Subst Use Misuse 2010;45:47-57.
15. Sher I, McGinn L, Sirey JA, Meyers B. Effects of caregivers’ perceived stigma and causal beliefs on patients’ adherence to antidepressant treatment. Psychiatr Serv 2005;56: 564-9.
16. Cunningham JA, Sobell LC, Sobell MB, Agrawal S, Toneatto T. Barriers to treatment: Why alcohol and drug abusers delay or never seek treatment. Addict Behav 1993;18:347-53.
17. The WHOQOL Group. Development of the World Health Organization WHOQOL-BREF quality of life assessment. Psychol Med 1998;28:551-8.
18. Skaugum ST, Lotfy M, O’Connell KA. The World Health Organization’s WHOQOL-BREF quality of life assessment: Psychometric properties and results of the international field trial. A report from the WHOQOL group. Qual Life Res 2004;13:299-310.
19. Saxena S, Chandiramani K, Bhargava R.WHOQOL-Hindi: A questionnaire for assessing quality of life in health care settings in India. Nat Med J Ind 1998;11:160-5.
20. Mattoo SK, Sarkar S, Gupta S, Nehhinani N, Parakh P, Basu D. Stigma towards substance use: Comparing treatment seeking alcohol and opioid dependent men. Int J Ment Health Addict 2015;13:73-81.
21. Mattoo SK, Sarkar S. Validation of Hindi version of perceived stigma of substance abuse scale. Indian J Soc Psychiatry 2012;28:117-20.
22. Giri OP, Srivastava M, Shankar R. Quality of life and health of opioid dependent subjects in India. J Neurosci Rural Pract 2014;5:363-8.
23. Luoma JB, Twohig MP, Waltz T, Hayes SC, Roget N, Padilla M, et al. An investigation of stigma in individuals receiving treatment for substance abuse. Addict Behav 2007;32:1331-46.
24. Oliveira SE, Carvalho H, Esteves F. Internalized stigma and quality of life domains among people with mental illness: The mediating role of self-esteem. J Ment Health 2016;25:55-61.
25. Keyes KM, Hatzenbuehler ML, McLaughlin KA, Link B, Olsson M, Grant BF, et al. Stigma and treatment for alcohol disorders in the United States. Am J Epidemiol 2010;172:1364-72.
26. Feeleymer JF, Des Jarlais DC, Arasteh K, Phillips BW, Hagan H. Changes in quality of life (WHOQOL-BREF) and addiction severity index (ASI) among participants in opioid substitution treatment (OST) in low and middle income countries: An international systematic review. Drug Alcohol Depend 2014;134:251-8.
27. Corrigan PW, Niewegolowski K. Stigma and the public health agenda for the opioid crisis in America. Int J Drug Policy 2018;59:44-9.